Targeted Delivery of RNA-based Therapeutics by Lipid Nanoparticles
Shayeri Chatterjee Ganguly, Priya Manna, Satadeep Bandyapadhyay, Dipanjan Karati, Niladri Sekhar Roy, Swarupananda Mukherjee, Dhrubajyoti Sarkar, Tathagata Dey, Rajesh Kesarla, Bikash BanerjeeAbstract:
Lipid Nanoparticles (LNPs) have emerged as adaptable and effective delivery systems for RNA-based therapies, transforming contemporary medicine. This article covers the design, processes, and therapeutic potential of LNPs for RNA delivery. LNPs improve RNA encapsulation, stability, and targeted cellular delivery. Lipid nanoparticles protect RNA molecules from enzymatic degradation, enable endosomal escape, and allow cytoplasmic release for gene control or functional translation. Various RNA types are delivered using LNPs for specific therapeutic applications, such as mRNA for vaccines and protein replacement, siRNA for gene silencing in diverse genetic and oncological conditions, miRNA for gene expression modulation, and CRISPR/Cas9 components for targeted gene editing. LNP-mediated RNA therapies have demonstrated efficacy across a diverse array of diseases. The design and optimization of LNPs depend on several factors. In vivo studies and preclinical models have confirmed their safety and efficacy, leading to successful clinical trials and FDA-approved RNAbased therapies. However, challenges encompass immunogenicity, limited tissue selectivity, substantial production requirements, and longer safety duration. Recent advancements in ionizable lipid chemistry, microfluidic formulation, and targeted delivery techniques are broadening the therapeutic potential of LNPs, reinforcing their significance as essential carriers in the forthcoming era of precision RNA medicine.